Form 4: Varex Director Sells Shares Under Pre-Arranged Plan
Insider Transaction Report
Varex Imaging Corp Director Jay K. Kunkel sold 4,510 shares of common stock for $11.14 per share, executed under a Rule 10b5-1 plan.
Summary
- Jay K. Kunkel, a Director of Varex Imaging Corp (VREX), sold 4,510 shares of the company's common stock.
- The transaction occurred on March 20, 2026, at a price of $11.14 per share.
- Following this sale, Kunkel directly beneficially owns 23,450 shares of Varex Imaging Corp common stock.
- The sale was conducted pursuant to a Rule 10b5-1 pre-arranged trading plan, which was indicated by checking the relevant box on the Form 4.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event. While an insider sale can sometimes be perceived negatively, the execution under a Rule 10b5-1 plan suggests a pre-planned liquidity event rather than a signal of declining confidence in the company's prospects.
Positives
- The transaction was executed under a Rule 10b5-1 plan, indicating a pre-scheduled sale rather than a reaction to new, non-public information.
Negatives
- A director selling shares, even under a 10b5-1 plan, reduces their direct ownership in the company.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
StockSavvy.ai notes that insider sales, even those pre-scheduled under Rule 10b5-1 plans, are routinely monitored by investors for potential signals regarding management's confidence. In the medical imaging industry, such transactions are typically viewed in the context of broader market conditions and company-specific news, though this particular filing provides no additional context beyond the transaction itself.
Comparison to Industry Standards
- This Form 4 filing reports a routine insider transaction. There are no specific company or project results to compare against global benchmarks or specific comparable companies.
- Insider trading activity is common across all industries, and the use of a Rule 10b5-1 plan aligns with best practices for executives to manage their personal holdings while avoiding accusations of trading on material non-public information.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Grant | Jay K. Kunkel granted a Power of Attorney to Matthew Martinez, Sunny Sanyal, Shubham Maheshwari, Richard Ludlow, Mckay Johnson, and Brian Qualls to prepare, execute, and submit SEC Forms ID, 3, 4, and 5 on his behalf. | 02/13/2026 | This is a standard corporate governance practice to ensure timely compliance with Section 16(a) reporting requirements for directors and officers. |
Stakeholder Impact
- Shareholders: May observe a slight reduction in director ownership, but the Rule 10b5-1 plan mitigates concerns about immediate negative sentiment.
- Employees, Customers, Suppliers, Creditors: No direct impact is indicated by this routine insider transaction filing.
Key Dates
| Date | Description |
|---|---|
| 02/13/2026 | Date Power of Attorney was executed by Jay K. Kunkel. |
| 03/20/2026 | Date of transaction where Jay K. Kunkel sold common stock. |
| 03/23/2026 | Date the Form 4 was signed by Matthew A. Martinez, attorney-in-fact. |
Recommendation
holdThe sale of shares by a director, while reducing insider ownership, was conducted under a pre-arranged Rule 10b5-1 plan. This suggests a planned liquidity event rather than a reaction to new, material information. Therefore, this specific transaction alone does not provide a strong enough signal to warrant a change in investment recommendation, maintaining a 'hold' stance based solely on this filing.
Keywords
Varex Imaging Corp, VREX, Form 4, Insider Trading, Stock Sale, Director, Jay K. Kunkel, Rule 10b5-1, Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.